Literature DB >> 26722286

Successful treatment of two consecutive cases of pulmonary pleomorphic carcinoma with platinum chemotherapy.

Daisuke Kato1, Yuichi Chihara1, Tomoyuki Shirase2, Tamaki Takahashi1, Ken-Ichi Takahashi1, Naoki Sakai1.   

Abstract

Pulmonary pleomorphic carcinoma (PPC) is a rare pulmonary malignant tumor that has a more aggressive clinical course and a poorer prognosis compared with non-small cell lung cancer (NSCLC) due to its resistance to chemotherapy and radiotherapy. In patients with advanced or relapsed PPC, it has been reported that the response rate to chemotherapy regimens known to be effective in patients with NSCLC is only 0-17%. The present study reports the cases of two consecutive patients with advanced PPC who exhibited marked responses to chemotherapy with carboplatin plus paclitaxel chemotherapy and long-term survival without tumor progression. This suggests that carboplatin plus paclitaxel chemotherapy is a good option for the treatment of advanced PPC.

Entities:  

Keywords:  chemotherapy; pulmonary pleomorphic carcinoma; taxanes

Year:  2015        PMID： 26722286      PMCID： PMC4665227          DOI： 10.3892/ol.2015.3678

Source DB:  PubMed          Journal:  Oncol Lett        ISSN： 1792-1074            Impact factor:   2.967


  14 in total

1.  Two consecutive cases of platinum-refractory pulmonary pleomorphic carcinoma that showed dramatic responses to MAID (mesna, doxorubicin, ifosfamide and dacarbazine) chemotherapy.

Authors:  Keun-Wook Lee; Yu Jung Kim; Jee Hyun Kim; Soo-Mee Bang; Jin-Haeng Chung; Jong Seok Lee
Journal:  Jpn J Clin Oncol       Date:  2010-10-05       Impact factor: 3.019

2.  Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung.

Authors:  Joon Suk Park; Yongjik Lee; Joungho Han; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Young Mog Shim; Kwhanmien Kim
Journal:  Oncology       Date:  2011-11-09       Impact factor: 2.935

3.  Sarcomatoid carcinoma of the prostate. A clinicopathologic study of 12 patients.

Authors:  R L Shannon; J Y Ro; D J Grignon; N G Ordóñez; D E Johnson; B Mackay; B Têtu; A G Ayala
Journal:  Cancer       Date:  1992-06-01       Impact factor: 6.860

Review 4.  The new World Health Organization classification of lung tumours.

Authors:  E Brambilla; W D Travis; T V Colby; B Corrin; Y Shimosato
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

5.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

6.  Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases.

Authors:  Giulio Rossi; Alberto Cavazza; Nathalie Sturm; Mario Migaldi; Nicola Facciolongo; Lucia Longo; Antonio Maiorana; Elisabeth Brambilla
Journal:  Am J Surg Pathol       Date:  2003-03       Impact factor: 6.394

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Palliative chemotherapy for pulmonary pleomorphic carcinoma.

Authors:  Hyun-Mi Bae; Hye Sook Min; Se-Hoon Lee; Dong-Wan Kim; Doo Hyun Chung; Jong-Seok Lee; Young Whan Kim; Dae Seog Heo
Journal:  Lung Cancer       Date:  2007-06-18       Impact factor: 5.705

9.  The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.

Authors:  Jung Yong Hong; Moon Ki Choi; Ji Eun Uhm; Min Jae Park; Jeeyun Lee; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Joung Ho Han; Myung Ju Ahn
Journal:  Med Oncol       Date:  2008-11-07       Impact factor: 3.064

10.  Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases.

Authors:  Takahiro Mochizuki; Genichiro Ishii; Kanji Nagai; Junji Yoshida; Mitsuyo Nishimura; Tetsuya Mizuno; Tomoyuki Yokose; Kazuya Suzuki; Atsushi Ochiai
Journal:  Am J Surg Pathol       Date:  2008-11       Impact factor: 6.394
View more
  4 in total

1.  Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.

Authors:  Shinichiro Okauchi; Yuika Sasatani; Toshihiro Shiozawa; Hideyasu Yamada; Kunihiko Miyazaki; Norio Takayashiki; Hiroaki Satoh
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Successful Treatment of Pulmonary Pleomorphic Carcinoma with Nivolumab: A Case Report.

Authors:  Eriko Fujimoto; Takashi Yokoi; Koji Mikami; Shingo Kanemura; Eisuke Shibata; Daisuke Horio; Yuichi Koda; Yoshiki Negi; Yumiko Akano; Akio Tada; Toshiyuki Minami; Kozo Kuribayashi; Takashi Kijima
Journal:  Case Rep Oncol       Date:  2018-05-31

3.  Clinicopathological characteristics, survival outcomes and prognostic factors in pleomorphic carcinoma: a SEER population-based study.

Authors:  Zhongzhong Chen; Jiachang Liu; Lingfeng Min
Journal:  BMC Pulm Med       Date:  2022-03-31       Impact factor: 3.317

4.  Long-term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report.

Authors:  Takafumi Yorozuya; Tetsuya Taya; Kento Yasuda; Yutaro Nagano; Makoto Shioya; Hirofumi Chiba; Hiroki Takahashi
Journal:  Thorac Cancer       Date:  2020-02-11       Impact factor: 3.500
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.